- Home
- AQST vs EBS Comparison
AQST vs EBS Comparison
Compare AQST & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- EBS
- Stock Information
- Founded
- AQST 2004
- EBS 1998
- Country
- AQST United States
- EBS United States
- Employees
- AQST N/A
- EBS N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- AQST Health Care
- EBS Health Care
- Exchange
- AQST Nasdaq
- EBS Nasdaq
- Market Cap
- AQST 502.6M
- EBS 459.6M
- IPO Year
- AQST 2018
- EBS 2006
- Fundamental
- Price
- AQST $3.80
- EBS $8.57
- Analyst Decision
- AQST Strong Buy
- EBS Strong Buy
- Analyst Count
- AQST 8
- EBS 2
- Target Price
- AQST $10.38
- EBS $14.00
- AVG Volume (30 Days)
- AQST 1.5M
- EBS 906.2K
- Earning Date
- AQST 11-04-2024
- EBS 11-06-2024
- Dividend Yield
- AQST N/A
- EBS N/A
- EPS Growth
- AQST N/A
- EBS N/A
- EPS
- AQST N/A
- EBS N/A
- Revenue
- AQST $58,900,000.00
- EBS $1,125,500,000.00
- Revenue This Year
- AQST $18.45
- EBS $6.64
- Revenue Next Year
- AQST N/A
- EBS $7.95
- P/E Ratio
- AQST N/A
- EBS N/A
- Revenue Growth
- AQST 22.56
- EBS 2.05
- 52 Week Low
- AQST $1.84
- EBS $1.42
- 52 Week High
- AQST $6.23
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- AQST 36.14
- EBS 43.37
- Support Level
- AQST $3.56
- EBS $8.36
- Resistance Level
- AQST $3.92
- EBS $9.03
- Average True Range (ATR)
- AQST 0.23
- EBS 0.46
- MACD
- AQST -0.05
- EBS -0.08
- Stochastic Oscillator
- AQST 13.91
- EBS 11.64
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.